At Cytodigm, we believe the future of genetic medicine will be defined not only by scientific discovery, but by how effectively therapies are delivered – and how closely innovators work together to bring them to patients. Partnership is central to our mission.
Cytodigm develops proprietary lipid-based nanoparticle (LNP) delivery platforms engineered for precision, targetability, and efficiency, addressing critical challenges such as tissue distribution, potency, and redosability. Our technologies are designed to support a wide range of modalities, including gene editing tools, in vivo CAR constructs, mRNA and vaccine applications, and next-generation RNAi therapeutics.
We work alongside biotech and pharmaceutical partners to integrate our delivery platforms with their therapeutic biology, tailoring solutions to specific research programs and disease targets. Through this approach, we accelerate development, expand therapeutic reach, and reduce risk across cell, gene, and immune-based therapies.
Together, we are creating a new paradigm in genetic medicine — one where transformative in vivo therapies can safely and reliably reach every patient.
Cytodigm’s delivery platforms have proven their success by packaging a variety of therapeutic payloads and delivering them to different disease sites. Zetafinity® polymeric nanoparticles, for instance, are most suitable for delivering small molecules, peptides, and proteins to immune cells to treat autoimmune diseases and cancer. This technology platform has been out-licensed for disease indications outside of oncology, and numerous programs of our licensee and sublicensees are in late-stage clinical trials, a testament to the effectiveness of this delivery platform.
Cytofinity™ lipid nanoparticle (LNP) is a tool for active targeting without the use of antibody conjugation. It transports siRNA, ASO, mRNA, DNA, gene-editing constructs, circular RNA, and other nucleic acid-based therapeutics to different cells and tissues. Cytodigm is open to collaborating with other biopharmaceutical companies to utilize Cytofinity™ LNPs to enhance the therapeutic impact of in vivo cell, gene, and immune therapy for patients.
Cytodigm’s technologies are covered by its extensive intellectual property portfolio and are potentially available for licensing as part of a collaboration. For any collaboration opportunities, please contact info@cytodigm.com.
